These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 10030501)
21. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old. Beran J; De Clercq N; Dieussaert I; Van Hoecke C Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024 [TBL] [Abstract][Full Text] [Related]
22. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination. Molloy PJ; Berardi VP; Persing DH; Sigal LH Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394 [TBL] [Abstract][Full Text] [Related]
23. New vaccine targets Lyme disease. New hope for diminishing the 'great masquerader'. Lewis C FDA Consum; 1999; 33(3):12-7. PubMed ID: 10443184 [No Abstract] [Full Text] [Related]
24. ACIP issues recommendations for Lyme disease vaccine. Advisory Committee on Immunization Practices. Morey SS Am Fam Physician; 1999 Nov; 60(7):2171-2. PubMed ID: 10569515 [No Abstract] [Full Text] [Related]
25. Lyme disease vaccines. Gardner P Ann Intern Med; 1998 Oct; 129(7):583-5. PubMed ID: 9758582 [No Abstract] [Full Text] [Related]
26. The cost effectiveness of vaccinating against Lyme disease. Meltzer MI; Dennis DT; Orloski KA Emerg Infect Dis; 1999; 5(3):321-8. PubMed ID: 10341168 [TBL] [Abstract][Full Text] [Related]
27. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease. Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567 [TBL] [Abstract][Full Text] [Related]
28. [Prevention of Lyme disease]. Kondrusik M; Zajkowska J; Pancewicz S; Hermanowska-Szpakowicz T Med Pr; 1999; 50(4):321-4. PubMed ID: 10582211 [TBL] [Abstract][Full Text] [Related]
29. Acquired resistance to Borrelia burgdorferi infection in the rabbit. Comparison between outer surface protein A vaccine- and infection-derived immunity. Foley DM; Wang YP; Wu XY; Blanco DR; Lovett MA; Miller JN J Clin Invest; 1997 Apr; 99(8):2030-5. PubMed ID: 9109448 [TBL] [Abstract][Full Text] [Related]
30. Need for a New Lyme Disease Vaccine. Plotkin SA N Engl J Med; 2016 Sep; 375(10):911-3. PubMed ID: 27602662 [No Abstract] [Full Text] [Related]
31. The ABCs of Lyme disease spirochaetes in ticks. Munderloh UG; Kurtti TJ Lancet; 2005 Sep 17-23; 366(9490):962-4. PubMed ID: 16168758 [No Abstract] [Full Text] [Related]
32. Studies on OspA: a source of new paradigms in Lyme disease research. Philipp MT Trends Microbiol; 1998 Feb; 6(2):44-7. PubMed ID: 9507636 [No Abstract] [Full Text] [Related]
33. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. Keller D; Koster FT; Marks DH; Hosbach P; Erdile LF; Mays JP JAMA; 1994 Jun; 271(22):1764-8. PubMed ID: 8196120 [TBL] [Abstract][Full Text] [Related]
34. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis. Fawcett PT; Rose CD; Budd SM; Gibney KM Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199 [TBL] [Abstract][Full Text] [Related]
35. Treatment of Lyme disease. Med Lett Drugs Ther; 2000 May; 42(1077):37-9. PubMed ID: 10825919 [No Abstract] [Full Text] [Related]
36. A role for T cells in the pathogenesis of treatment-resistant Lyme arthritis. Kamradt T; Krause A; Burmester GR Mol Med; 1995 Jul; 1(5):486-90. PubMed ID: 8529115 [No Abstract] [Full Text] [Related]